LRT Capital Management’s AbbVie ABBV Stock Holding History

LRT Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,508	Closed	-$763K	–	65
2026 Q1	$763K	Buy	+3,508	New	+$778K	0.71%	54

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LRT Capital Management's ABBV Position: Q2 2026 in Review

LRT Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 3,508 shares — an estimated $763K sold.

LRT Capital Management first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $763K in Q1 2026. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

LRT Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
LRT Capital Management sold 3,508 AbbVie shares in Q2 2026, an estimated $763K.
LRT Capital Management first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
LRT Capital Management's AbbVie position peaked at $763K in Q1 2026.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on LRT Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.